shutterstock_1891094320_guteksk7

guteksk7 / Shutterstock.com

14 July 2022Americas

Moderna, Pfizer face escalating COVID vaccine patent suits

New lawsuit comes months after the pair were accused of infringing lipid nanoparticle technology.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Alnylam says Moderna used patented tech to make vaccine

22 March 2022 Alnylam Pharmaceuticals has accused Moderna of using its nanoparticle technology to develop its COVID-19 vaccine.

CureVac sues BioNTech over mRNA technology

7 July 2022 Germany-based CureVac has accused BioNTech of infringing four patents related to messenger ribonucleic acid technology.

Vaccine makers hit back against patent claims

28 July 2022 German biotech and its US big pharma partner file counter complaint | Under-fire pair say they didn’t infringe patents | Claims reject earlier suit as an attempt to profit through legal threats.

More on this story

Alnylam says Moderna used patented tech to make vaccine

22 March 2022 Alnylam Pharmaceuticals has accused Moderna of using its nanoparticle technology to develop its COVID-19 vaccine.

CureVac sues BioNTech over mRNA technology

7 July 2022 Germany-based CureVac has accused BioNTech of infringing four patents related to messenger ribonucleic acid technology.

Vaccine makers hit back against patent claims

28 July 2022 German biotech and its US big pharma partner file counter complaint | Under-fire pair say they didn’t infringe patents | Claims reject earlier suit as an attempt to profit through legal threats.

More on this story

Alnylam says Moderna used patented tech to make vaccine

22 March 2022 Alnylam Pharmaceuticals has accused Moderna of using its nanoparticle technology to develop its COVID-19 vaccine.

CureVac sues BioNTech over mRNA technology

7 July 2022 Germany-based CureVac has accused BioNTech of infringing four patents related to messenger ribonucleic acid technology.

Vaccine makers hit back against patent claims

28 July 2022 German biotech and its US big pharma partner file counter complaint | Under-fire pair say they didn’t infringe patents | Claims reject earlier suit as an attempt to profit through legal threats.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York